3 Key Takeaways
Plain English Summary- 01Core Finding
Identifying childhood cancer survivors with CPS is essential to improving overall outcomes by informing tailored approaches to cancer screening, treatment, and, for some, risk-reducing interventions.
- 02Study Evidence
Tested in a observational cohort study at the real-world cohort stage.
- 03Practical Meaning
Observational cohort findings reveal real-world links, though lifestyle or unmeasured factors cannot be fully ruled out without an RCT.
What This Means for You
This Policy Review details the importance, development, and anticipated impact of this new guideline. Raising awareness of this guideline is crucial to enhancing the integration of genetics into survivorship care and improving health outcomes for childhood cancer survivors with CPS.
The Discovery
substantially of childhood cancer survivors have an underlying cancer predisposition syndrome (CPS). As a result, these childhood cancer survivors are at increased risk for developing and succumbing to subsequent malignant neoplasms. Identifying childhood cancer survivors with CPS is essential to improving overall outcomes by informing tailored approaches to cancer screening, treatment, and, for some, risk-reducing interventions. Despite these potential benefits, it is often unclear which childhood cancer survivors warrant referral for genetic counselling and germline genetic testing. Using an evidence-based approach, a standardised guideline for referral for cancer genetics evaluation of childhood cancer survivors at high risk of having a CPS was developed and incorporated into the Children's Oncology Group Long-Term Follow-Up Guidelines for Survivors of Childhood, Adolescent, and Young Adult Cancers.
How It Works, Simply
This oncology research focuses on genetics. Researchers evaluated it using an observational cohort study at the real-world cohort stage of medical research.
3 Key Takeaways
Clinical Takeaways- 01Core Finding
Identifying childhood cancer survivors with CPS is essential to improving overall outcomes by informing tailored approaches to cancer screening, treatment, and, for some, risk-reducing interventions.
- 02Study Evidence
Tested in a observational cohort study at the real-world cohort stage.
- 03Practical Meaning
Observational cohort findings reveal real-world links, though lifestyle or unmeasured factors cannot be fully ruled out without an RCT.
Biological Mechanism & Study Design
Study Design & Cohort
Observational cohort study
Observational cohort study · Real-World Cohort
Biological Pathway & Modality
Genetics
Intervention: Development of the Children's Oncology Group long-term follow-up guideline for
Experimental Findings & Endpoints
substantially of childhood cancer survivors have an underlying cancer predisposition syndrome (CPS).
As a result, these childhood cancer survivors are at increased risk for developing and succumbing to subsequent malignant neoplasms. Identifying childhood cancer survivors with CPS is essential to improving overall outcomes by informing tailored approaches to cancer screening, treatment, and, for some, risk-reducing interventions.
Despite these potential benefits, it is often unclear which childhood cancer survivors warrant referral for genetic counselling and germline genetic testing. Using an evidence-based approach, a standardised guideline for referral for cancer genetics evaluation of childhood cancer survivors at high risk of having a CPS was developed and incorporated into the Children's Oncology Group Long-Term Follow-Up Guidelines for Survivors of Childhood, Adolescent, and Young Adult Cancers.
Clinical Translation & Practice Context
This Policy Review details the importance, development, and anticipated impact of this new guideline.
Raising awareness of this guideline is crucial to enhancing the integration of genetics into survivorship care and improving health outcomes for childhood cancer survivors with CPS.
The Bottom Line · Clinical Pearl
“Raising awareness of this guideline is crucial to enhancing the integration of genetics into survivorship care and improving health outcomes for childhood cancer survivors with CPS.”
Published in The Lancet Oncology · Current Stage: Real-World Cohort